Needham analyst says, "We expect significant upside to NUVA’s share price if NUVA continues to meet or beat numbers and demonstrates EPS leverage in 2010. 
Share:  <span class="sent"><span class="analyst">Needham</span> analyst says, "We expect significant upside to NUVA’s share price if NUVA continues to meet or beat numbers and demonstrates EPS leverage in 2010.</span> Tweet this   read full story

Raj Denhoy, analyst at Jefferies, has a Buy rating on NuVasive (NYSE: NUVA), a medical device company focused on products for the surgical treatment of the spine. The stock has been trading at $40.20 and Denhoy has a target price of $51.00 on the shares. . Growth of spinal medical products is slowing down but that should not deter NuVasive from achieving its growth objectives. The company is launching new products and there is still no real competition for its products like XLIF and NeuroVision. 
Share:  <span class="sent"><span class="analyst">Raj Denhoy</span>, analyst at Jefferies, has a Buy rating on <span class="company">NuVasive</span> (NYSE: NUVA), a medical device company focused on products for the surgical treatment of the spine.</span> The stock has been trading at $40.20 and Denhoy has a target price of $51.00 on the shares. . Growth of spinal medical products is slowing down but that should not deter <span class="company">NuVasive</span> from achieving its growth objectives. The company is launching new products and there is still no real competition for its products like XLIF and NeuroVision. Tweet this   read full story

We are initiating our issuer credit rating for NuVasive NUVA at BBB , reflecting its improving competitive position and cash flow trends. NuVasive's Maximum Access Surgery platform offers a novel approach to spinal fusion surgeries with a lateral approach through the side and a cutting edge visualization system that helps surgeons safely navigate around nerves. The firm's system and implants enable a technique that helps surgeons reduce procedure time, minimize blood loss, and enable faster recoveries. 
Share:  We are initiating our issuer credit rating for <span class="company">NuVasive</span> NUVA at BBB , reflecting its improving competitive position and cash flow trends. <span class="company">NuVasive</span>'s Maximum Access Surgery platform offers a novel approach to spinal fusion surgeries with a lateral approach through the side and a cutting edge visualization system that helps surgeons safely navigate around nerves. The firm's system and implants enable a technique that helps surgeons reduce procedure time, minimize blood loss, and enable faster recoveries. Tweet this   read full story